TapewireFind a company

person · Reporting owner

Boulding Mark Elliott

Disclosed activity across 1 company

Tapewire entity
21799
SEC CIK
0001578852

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
PTC THERAPEUTICS, INC.PTCT · Entity 3803EXEC. VP AND CLOOctober 09, 2026October 13, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

PTC THERAPEUTICS, INC.

Report date October 09, 2026 · Filed October 13, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect105,272 Ending reported balance After 2026-10-09 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2026-10-09 · Exercise / conversion · Acquired 192 · Balance 105,464

F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.

Row 2 · 2026-10-09 · Sale · Disposed 192 · Balance 105,272

F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.

F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.42 · Expires 2033-01-04Direct2,267 Reported balance After 2026-10-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2026-10-09 · Exercise / conversion · Disposed 192 · Balance 2,267

F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.

F3: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.

F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.00 to $64.70 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

F3: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 19, 2026 Filed Feb 23, 2026 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 212 $68.54 $14,530.48
Disclosure

SEC source: 0001578852-26-000010 · form4-02232026_050201.xml · nonDerivative · entry 3

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,802

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.

F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $67.99 to $68.93 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
February 19, 2026 Filed Feb 23, 2026 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 1,629 $69.82 $113,736.78
Disclosure

SEC source: 0001578852-26-000010 · form4-02232026_050201.xml · nonDerivative · entry 2

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 106,014

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.

F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $69.52 to $70.18 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
February 19, 2026 Filed Feb 23, 2026 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 588 $68.54 $40,301.52
Disclosure

SEC source: 0001578852-26-000010 · form4-02232026_050201.xml · nonDerivative · entry 1

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 107,643

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.

F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $67.99 to $68.93 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
February 18, 2026 Filed Feb 19, 2026 22:25 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 3,081 $69.36 $213,698.16
Disclosure

SEC source: 0001578852-26-000008 · form4-02192026_050201.xml · nonDerivative · entry 4

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 108,231

F3 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,500 RSUs from a February 15, 2024 grant of 18,000 RSUs and the vesting of 1,600 RSUs from a February 15, 2024 grant of 3,200 RSUs.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 22:25 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 2,813 $0.00 Strike: $25.69 $0.00
Disclosure

SEC source: 0001578852-26-000008 · form4-02192026_050201.xml · derivative · entry 5

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,501

Underlying: Common Stock · 2,813 shares

Expires 2034-02-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.

F4 · derivative.exercise_date: Currently exercisable.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 22:25 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 2 $70.13 $140.26
Disclosure

SEC source: 0001578852-26-000008 · form4-02192026_050201.xml · nonDerivative · entry 3

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 111,312

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 22:25 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 2,811 $69.29 $194,774.19
Disclosure

SEC source: 0001578852-26-000008 · form4-02192026_050201.xml · nonDerivative · entry 2

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 111,314

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.

F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $68.84 to $69.80 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
February 17, 2026 Filed Feb 19, 2026 22:25 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 2,813 $25.69 $72,265.97
Disclosure

SEC source: 0001578852-26-000008 · form4-02192026_050201.xml · nonDerivative · entry 1

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 114,125

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.

Read SEC document
January 09, 2026 Filed Jan 12, 2026 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 107 $79.52 $8,508.64
Disclosure

SEC source: 0001578852-26-000006 · form4-01122026_050103.xml · nonDerivative · entry 6

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 111,312

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.

F7 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $79.35 to $79.60 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
January 09, 2026 Filed Jan 12, 2026 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 686 $78.71 $53,995.06
Disclosure

SEC source: 0001578852-26-000006 · form4-01122026_050103.xml · nonDerivative · entry 5

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 111,419

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.

F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $78.23 to $79.21 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
January 09, 2026 Filed Jan 12, 2026 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 1,521 $77.46 $117,816.66
Disclosure

SEC source: 0001578852-26-000006 · form4-01122026_050103.xml · nonDerivative · entry 4

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 112,105

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.

F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $77.12 to $78.08 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
January 08, 2026 Filed Jan 12, 2026 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 1,286 $76.45 $98,314.70
Disclosure

SEC source: 0001578852-26-000006 · form4-01122026_050103.xml · nonDerivative · entry 3

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 113,626

F4 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 3,600 RSUs from a January 7, 2022 grant of 14,400 RSUs.

Read SEC document
January 08, 2026 Filed Jan 12, 2026 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 265 $77.07 $20,423.55
Disclosure

SEC source: 0001578852-26-000006 · form4-01122026_050103.xml · nonDerivative · entry 2

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 114,912

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.

F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $76.99 to $77.23 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
January 08, 2026 Filed Jan 12, 2026 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 2,482 $76.56 $190,021.92
Disclosure

SEC source: 0001578852-26-000006 · form4-01122026_050103.xml · nonDerivative · entry 1

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 115,177

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.

F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $75.95 to $76.92 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
January 07, 2026 Filed Jan 8, 2026 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 751 $0.00 Strike: $38.10 $0.00
Disclosure

SEC source: 0001578852-26-000004 · form4-01082026_050104.xml · derivative · entry 12

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 751 shares

Expires 2032-01-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.

F8 · derivative.exercise_date: Currently exercisable.

Read SEC document
January 07, 2026 Filed Jan 8, 2026 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 2,625 $0.00 Strike: $38.10 $0.00
Disclosure

SEC source: 0001578852-26-000004 · form4-01082026_050104.xml · derivative · entry 11

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 751

Underlying: Common Stock · 2,627 shares

Expires 2032-01-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.

F8 · derivative.exercise_date: Currently exercisable.

Read SEC document
January 07, 2026 Filed Jan 8, 2026 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 11 $78.98 $868.78
Disclosure

SEC source: 0001578852-26-000004 · form4-01082026_050104.xml · nonDerivative · entry 10

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 117,659

F3 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.

Read SEC document
January 07, 2026 Filed Jan 8, 2026 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 269 $77.92 $20,960.48
Disclosure

SEC source: 0001578852-26-000004 · form4-01082026_050104.xml · nonDerivative · entry 9

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 117,670

F3 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.

F7 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $77.54 to $78.47 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
January 07, 2026 Filed Jan 8, 2026 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 471 $77.10 $36,314.10
Disclosure

SEC source: 0001578852-26-000004 · form4-01082026_050104.xml · nonDerivative · entry 8

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 117,939

F3 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.

F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $76.54 to $77.52 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
January 07, 2026 Filed Jan 8, 2026 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 751 $38.10 $28,613.10
Disclosure

SEC source: 0001578852-26-000004 · form4-01082026_050104.xml · nonDerivative · entry 7

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 118,410

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.

Read SEC document
January 07, 2026 Filed Jan 8, 2026 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 38 $78.60 $2,986.80
Disclosure

SEC source: 0001578852-26-000004 · form4-01082026_050104.xml · nonDerivative · entry 6

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 117,659

F3 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.

Read SEC document
January 07, 2026 Filed Jan 8, 2026 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 949 $77.91 $73,936.59
Disclosure

SEC source: 0001578852-26-000004 · form4-01082026_050104.xml · nonDerivative · entry 5

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 117,697

F3 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.

F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $77.58 to $78.54 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
January 07, 2026 Filed Jan 8, 2026 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 1,638 $77.11 $126,306.18
Disclosure

SEC source: 0001578852-26-000004 · form4-01082026_050104.xml · nonDerivative · entry 4

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 118,646

F3 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.

F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $76.56 to $77.55 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
January 07, 2026 Filed Jan 8, 2026 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 2,625 $38.10 $100,012.50
Disclosure

SEC source: 0001578852-26-000004 · form4-01082026_050104.xml · nonDerivative · entry 3

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 120,284

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.

Read SEC document
January 07, 2026 Filed Jan 8, 2026 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 1,503 $77.48 $116,452.44
Disclosure

SEC source: 0001578852-26-000004 · form4-01082026_050104.xml · nonDerivative · entry 2

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 117,659

F2 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,250 RSUs from a January 5, 2023 grant of 17,000 RSUs.

Read SEC document
January 06, 2026 Filed Jan 8, 2026 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 1,739 $76.95 $133,816.05
Disclosure

SEC source: 0001578852-26-000004 · form4-01082026_050104.xml · nonDerivative · entry 1

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 119,162

F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,500 RSUs from a January 3, 2025 grant of 18,000 RSUs.

Read SEC document
January 05, 2026 Filed Jan 6, 2026 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 2,266 $0.00 Strike: $39.42 $0.00
Disclosure

SEC source: 0001578852-26-000002 · form4-01062026_050119.xml · derivative · entry 7

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,063

Underlying: Common Stock · 2,266 shares

Expires 2033-01-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.

F7 · derivative.exercise_date: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.

Read SEC document
January 05, 2026 Filed Jan 6, 2026 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 108 $76.79 $8,293.32
Disclosure

SEC source: 0001578852-26-000002 · form4-01062026_050119.xml · nonDerivative · entry 5

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 120,901

F2 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.

F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $76.75 to $76.81 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
January 05, 2026 Filed Jan 6, 2026 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 1,035 $76.10 $78,763.50
Disclosure

SEC source: 0001578852-26-000002 · form4-01062026_050119.xml · nonDerivative · entry 4

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 121,009

F2 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.

F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $75.58 to $76.42 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
January 05, 2026 Filed Jan 6, 2026 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 1,123 $74.92 $84,135.16
Disclosure

SEC source: 0001578852-26-000002 · form4-01062026_050119.xml · nonDerivative · entry 3

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 122,044

F2 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.

F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $74.55 to $75.27 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
January 05, 2026 Filed Jan 6, 2026 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 2,266 $39.42 $89,325.72
Disclosure

SEC source: 0001578852-26-000002 · form4-01062026_050119.xml · nonDerivative · entry 2

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 123,167

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 4, 2024.

Read SEC document
January 02, 2026 Filed Jan 6, 2026 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 GrantStock Option (Right to Buy) · Derivative 42,500 $0.00 Strike: $76.74 $0.00
Disclosure

SEC source: 0001578852-26-000002 · form4-01062026_050119.xml · derivative · entry 6

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 42,500

Underlying: Common Stock · 42,500 shares

Expires 2036-01-01

F6 · derivative.exercise_date: This option was granted on January 2, 2026, and vests over four years, with 25% of the shares underlying the option vesting on January 2, 2027, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 2, 2027.

Read SEC document
January 02, 2026 Filed Jan 6, 2026 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 GrantCommon Stock 17,000 $0.00 $0.00
Disclosure

SEC source: 0001578852-26-000002 · form4-01062026_050119.xml · nonDerivative · entry 1

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 120,901

F1 · shares: Restricted stock units granted on January 2, 2026 that vest in four equal installments over four years, commencing on January 2, 2027.

Read SEC document
November 17, 2025 Filed Nov 19, 2025 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 2,812 $0.00 Strike: $25.69 $0.00
Disclosure

SEC source: 0001578852-25-000010 · form4-11192025_051101.xml · derivative · entry 5

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,314

Underlying: Common Stock · 2,812 shares

Expires 2034-02-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F5 · derivative.exercise_date: This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025.

Read SEC document
November 17, 2025 Filed Nov 19, 2025 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 192 $77.18 $14,818.56
Disclosure

SEC source: 0001578852-25-000010 · form4-11192025_051101.xml · nonDerivative · entry 4

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,901

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $77.10 to $77.33 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
November 17, 2025 Filed Nov 19, 2025 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 777 $76.53 $59,463.81
Disclosure

SEC source: 0001578852-25-000010 · form4-11192025_051101.xml · nonDerivative · entry 3

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 104,093

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $76.08 to $77.07 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
November 17, 2025 Filed Nov 19, 2025 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 1,843 $75.64 $139,404.52
Disclosure

SEC source: 0001578852-25-000010 · form4-11192025_051101.xml · nonDerivative · entry 2

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 104,870

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $75.06 to $76.04 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
November 17, 2025 Filed Nov 19, 2025 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 2,812 $25.69 $72,240.28
Disclosure

SEC source: 0001578852-25-000010 · form4-11192025_051101.xml · nonDerivative · entry 1

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 106,713

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

Read SEC document
October 07, 2025 Filed Oct 9, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 3,375 $0.00 Strike: $38.10 $0.00
Disclosure

SEC source: 0001578852-25-000008 · form4-10092025_051001.xml · derivative · entry 5

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,376

Underlying: Common Stock · 3,375 shares

Expires 2032-01-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F5 · derivative.exercise_date: This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023.

Read SEC document
October 07, 2025 Filed Oct 9, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 312 $64.97 $20,270.64
Disclosure

SEC source: 0001578852-25-000008 · form4-10092025_051001.xml · nonDerivative · entry 4

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,901

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.56 to $65.01 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
October 07, 2025 Filed Oct 9, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 1,306 $63.80 $83,322.80
Disclosure

SEC source: 0001578852-25-000008 · form4-10092025_051001.xml · nonDerivative · entry 3

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 104,213

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $63.36 to $64.25 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
October 07, 2025 Filed Oct 9, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 1,757 $62.89 $110,497.73
Disclosure

SEC source: 0001578852-25-000008 · form4-10092025_051001.xml · nonDerivative · entry 2

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,519

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $62.36 to $63.28 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
October 07, 2025 Filed Oct 9, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 3,375 $38.10 $128,587.50
Disclosure

SEC source: 0001578852-25-000008 · form4-10092025_051001.xml · nonDerivative · entry 1

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 107,276

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

Read SEC document
October 06, 2025 Filed Oct 7, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 2,266 $0.00 Strike: $39.42 $0.00
Disclosure

SEC source: 0001578852-25-000005 · form4-10072025_051003.xml · derivative · entry 19

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,329

Underlying: Common Stock · 2,266 shares

Expires 2033-01-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F13 · derivative.exercise_date: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.

Read SEC document
October 06, 2025 Filed Oct 7, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 2,266 $65.07 $147,448.62
Disclosure

SEC source: 0001578852-25-000005 · form4-10072025_051003.xml · nonDerivative · entry 15

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,901

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F12 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.72 to $65.38 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
October 06, 2025 Filed Oct 7, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 2,266 $39.42 $89,325.72
Disclosure

SEC source: 0001578852-25-000005 · form4-10072025_051003.xml · nonDerivative · entry 14

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 106,167

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

Read SEC document
October 03, 2025 Filed Oct 7, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 2,265 $0.00 Strike: $39.42 $0.00
Disclosure

SEC source: 0001578852-25-000005 · form4-10072025_051003.xml · derivative · entry 18

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,595

Underlying: Common Stock · 2,265 shares

Expires 2033-01-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F13 · derivative.exercise_date: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.

Read SEC document
October 03, 2025 Filed Oct 7, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 2,266 $0.00 Strike: $39.42 $0.00
Disclosure

SEC source: 0001578852-25-000005 · form4-10072025_051003.xml · derivative · entry 17

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,860

Underlying: Common Stock · 2,266 shares

Expires 2033-01-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F13 · derivative.exercise_date: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.

Read SEC document
October 03, 2025 Filed Oct 7, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 18,124 $0.00 Strike: $39.42 $0.00
Disclosure

SEC source: 0001578852-25-000005 · form4-10072025_051003.xml · derivative · entry 16

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 18,126

Underlying: Common Stock · 18,124 shares

Expires 2033-01-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F13 · derivative.exercise_date: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.

Read SEC document
October 03, 2025 Filed Oct 7, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 877 $66.67 $58,469.59
Disclosure

SEC source: 0001578852-25-000005 · form4-10072025_051003.xml · nonDerivative · entry 13

Boulding Mark Elliott · CIK 0001578852 · EXEC. VP AND CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,901

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 5, 2024.

F11 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.42 to $67.07 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.